PL376231A1 - Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate - Google Patents
Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoateInfo
- Publication number
- PL376231A1 PL376231A1 PL03376231A PL37623103A PL376231A1 PL 376231 A1 PL376231 A1 PL 376231A1 PL 03376231 A PL03376231 A PL 03376231A PL 37623103 A PL37623103 A PL 37623103A PL 376231 A1 PL376231 A1 PL 376231A1
- Authority
- PL
- Poland
- Prior art keywords
- inhalation
- salmeterol xinafoate
- powdered medicament
- tiotropium salt
- tiotropium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10259912 | 2002-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL376231A1 true PL376231A1 (en) | 2005-12-27 |
Family
ID=32404034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03376231A PL376231A1 (en) | 2002-12-20 | 2003-12-04 | Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1581198A1 (en) |
| JP (1) | JP2006516135A (en) |
| KR (1) | KR20050086930A (en) |
| CN (1) | CN1728988B (en) |
| AU (1) | AU2003288226B2 (en) |
| BR (1) | BR0317443A (en) |
| CA (1) | CA2510779A1 (en) |
| DE (1) | DE10351663A1 (en) |
| EA (1) | EA010588B1 (en) |
| EC (1) | ECSP055855A (en) |
| FR (1) | FR2848849B1 (en) |
| HR (1) | HRP20050570A2 (en) |
| IT (1) | ITMI20032473A1 (en) |
| MX (1) | MXPA05006519A (en) |
| NO (1) | NO20053548L (en) |
| NZ (1) | NZ541303A (en) |
| PL (1) | PL376231A1 (en) |
| RS (1) | RS20050484A (en) |
| UA (1) | UA83813C2 (en) |
| WO (1) | WO2004058233A1 (en) |
| ZA (1) | ZA200503692B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
| JP4342426B2 (en) * | 2004-11-24 | 2009-10-14 | 科研製薬株式会社 | Itraconazole formulation for oral administration |
| JP2009504603A (en) * | 2005-08-06 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method of treating dyspnea by administering a combination of tiotropium salt and salmeterol salt |
| EP2123650B1 (en) | 2005-12-19 | 2012-04-04 | Sicor, Inc. | Novel form of tiotropium bromide and process for preparation thereof |
| EA030606B1 (en) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Methods of preparing a medicament comprising polymorphs |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
| DE102007036411A1 (en) | 2007-07-20 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
| PE20090907A1 (en) * | 2007-07-21 | 2009-08-05 | Boehringer Ingelheim Int | NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT |
| PE20140960A1 (en) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
| UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
| BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| BRPI0923121A2 (en) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Saline forms of organic compounds |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| ES2760917T3 (en) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin |
| JP6034781B2 (en) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy |
| EA201991014A1 (en) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | DIABETES TREATMENT |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| MX366629B (en) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| KR101748796B1 (en) * | 2015-09-30 | 2017-06-19 | 한미약품 주식회사 | Inhalation capsule with enhanced delivery rate of active ingredients |
| JP2019517542A (en) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of linagliptin and metformin |
| CA3119145A1 (en) * | 2018-11-13 | 2020-05-22 | Cocrystal Pharma, Inc. | Formulations comprising 3-(2-(5-chloro-1h-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7h-pyrrolo[2,3-d]pyrimid-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid for the treatment of influenza |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056974C (en) * | 1992-02-11 | 2000-10-04 | 格拉克索公司 | Drug material suitable for micronisation |
| WO1993016031A1 (en) * | 1992-02-11 | 1993-08-19 | Glaxo Group Limited | Benzenedimethanol derivative suitable for micronisation |
| GB9313650D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| DE19921693A1 (en) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects |
| UA75375C2 (en) * | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
| DE10056104A1 (en) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts |
| DE10104367A1 (en) * | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Medicinal compositions containing betamimetics with fewer side effects |
| DE10130371A1 (en) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics, corticosteroids and betamimetics |
| JP2004537377A (en) * | 2001-08-09 | 2004-12-16 | グラクソ グループ リミテッド | Inhalation device with pharmaceutical composition |
| MXPA04002401A (en) * | 2001-09-14 | 2004-05-31 | Boehringer Ingelheim Pharma | Novel medicaments for inhalation. |
-
2003
- 2003-11-05 DE DE10351663A patent/DE10351663A1/en not_active Withdrawn
- 2003-12-04 EA EA200500902A patent/EA010588B1/en not_active IP Right Cessation
- 2003-12-04 UA UAA200507088A patent/UA83813C2/en unknown
- 2003-12-04 EP EP03780120A patent/EP1581198A1/en not_active Withdrawn
- 2003-12-04 RS YUP-2005/0484A patent/RS20050484A/en unknown
- 2003-12-04 JP JP2004562686A patent/JP2006516135A/en active Pending
- 2003-12-04 PL PL03376231A patent/PL376231A1/en not_active Application Discontinuation
- 2003-12-04 MX MXPA05006519A patent/MXPA05006519A/en unknown
- 2003-12-04 AU AU2003288226A patent/AU2003288226B2/en not_active Ceased
- 2003-12-04 CN CN2003801069216A patent/CN1728988B/en not_active Expired - Fee Related
- 2003-12-04 WO PCT/EP2003/013691 patent/WO2004058233A1/en active Application Filing
- 2003-12-04 NZ NZ541303A patent/NZ541303A/en unknown
- 2003-12-04 KR KR1020057011668A patent/KR20050086930A/en not_active Application Discontinuation
- 2003-12-04 CA CA002510779A patent/CA2510779A1/en not_active Abandoned
- 2003-12-04 BR BR0317443-3A patent/BR0317443A/en not_active IP Right Cessation
- 2003-12-16 IT IT002473A patent/ITMI20032473A1/en unknown
- 2003-12-19 FR FR0315082A patent/FR2848849B1/en not_active Expired - Fee Related
-
2005
- 2005-05-09 ZA ZA200503692A patent/ZA200503692B/en unknown
- 2005-06-15 EC EC2005005855A patent/ECSP055855A/en unknown
- 2005-06-17 HR HR20050570A patent/HRP20050570A2/en not_active Application Discontinuation
- 2005-07-19 NO NO20053548A patent/NO20053548L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2848849A1 (en) | 2004-06-25 |
| ITMI20032473A1 (en) | 2004-06-21 |
| CA2510779A1 (en) | 2004-07-15 |
| AU2003288226B2 (en) | 2010-01-07 |
| CN1728988B (en) | 2010-04-28 |
| FR2848849B1 (en) | 2007-01-05 |
| BR0317443A (en) | 2005-11-16 |
| EA010588B1 (en) | 2008-10-30 |
| ZA200503692B (en) | 2006-10-25 |
| MXPA05006519A (en) | 2005-08-26 |
| AU2003288226A1 (en) | 2004-07-22 |
| DE10351663A1 (en) | 2004-07-01 |
| ECSP055855A (en) | 2005-11-22 |
| HRP20050570A2 (en) | 2006-07-31 |
| EP1581198A1 (en) | 2005-10-05 |
| EA200500902A1 (en) | 2006-02-24 |
| UA83813C2 (en) | 2008-08-26 |
| NO20053548L (en) | 2005-09-02 |
| WO2004058233A1 (en) | 2004-07-15 |
| CN1728988A (en) | 2006-02-01 |
| RS20050484A (en) | 2007-11-15 |
| NZ541303A (en) | 2008-11-28 |
| KR20050086930A (en) | 2005-08-30 |
| JP2006516135A (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL376231A1 (en) | Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate | |
| ZA200705376B (en) | A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation | |
| EP1635762A4 (en) | Low dose pharmaceutical powders for inhalation | |
| EP1581281A4 (en) | Inhalation device for producing a drug aerosol | |
| IL156308A0 (en) | Metered dose inhaler for salmeterol xinafoate | |
| HK1078793A1 (en) | Aerosol formulation for inhalation comprising a tiotropium salt | |
| HK1087337A1 (en) | Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes | |
| EG23792A (en) | Inhalation device for transpulmonary administration | |
| IL221103B (en) | Inhaler for powdered substances particularly medical substances | |
| IL182634A0 (en) | Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy | |
| EP1898922A4 (en) | Improved drug or pharmaceutical compounds and a preparation thereof | |
| GB0313604D0 (en) | Delivery device for powdered medicament | |
| PL387118A1 (en) | Inhalation capsules comprising tiotropium and the use thereof | |
| GB0222295D0 (en) | Breath actuated medicament dispensing devices | |
| EP1685865A4 (en) | A syringe for powder medicament premixing | |
| HK1129111A1 (en) | Tiotropium salts, pharmaceutical formulations containing the salts and the use thereof | |
| GB0328630D0 (en) | Metered dose inhalation preparations | |
| IL181819A (en) | Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds | |
| HK1085918A1 (en) | Pulverulent formulation for inhalation containing tiotropium | |
| GB0714907D0 (en) | A resonating (alerting) metered dose inhaler | |
| EP1654312A4 (en) | Pharmaceutical metered dose inhaler and methods relating thereto | |
| TWI340649B (en) | A pharmaceutical composition containing alkaline medicament | |
| GB2406096B (en) | A pharmaceutical metered dose aerosol inhaler device | |
| ZA200406881B (en) | Medicaments containing betamimetic drugs and a novel anticholineterase drug | |
| GB0311701D0 (en) | Improved metered dose inhaler product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |